The FGD3 antibody targets the FGD3 protein, a member of the FYVE, RhoGEF, and PH domain-containing family, which functions as a guanine nucleotide exchange factor (GEF) for the Rho GTPase Cdc42. FGD3 regulates cellular processes such as cytoskeletal reorganization, cell polarity, and migration by activating Cdc42. a key mediator of signaling pathways influencing cell morphology and motility. Research has highlighted FGD3's dual role in cancer biology: it may act as a tumor suppressor in certain contexts, such as breast and colorectal cancers, where its downregulation or loss correlates with tumor progression, metastasis, and poor prognosis. Conversely, FGD3 overexpression has been linked to aggressive phenotypes in other cancers, suggesting context-dependent functions. The FGD3 antibody is a critical tool for studying these mechanisms, enabling detection and localization of FGD3 via techniques like Western blotting, immunohistochemistry, and immunofluorescence. It also facilitates exploration of FGD3's interactions within signaling networks and its potential as a therapeutic or diagnostic biomarker. Studies using this antibody have contributed to understanding how FGD3 dysregulation impacts oncogenesis, though its precise role remains under investigation, reflecting the complexity of Rho GTPase signaling in disease.